Introduction
============

HIV-infected individuals are at an increased risk of age-related non-AIDS morbidity and mortality compared with HIV-uninfected persons [@R1]. It is speculated that HIV-infected individuals may not only be ageing chronologically but also undergoing accelerated biological ageing mediated by increased cellular senescence [@R2]. Chronological age is an imprecise measure of biological ageing, due to inter-individual differences in rates of ageing. The disconnection between chronological age and lifespan has led to a search for effective and validated biomarkers of ageing (BoA), defined as 'biological parameters of an organism that either alone or in some multivariate composite will better predict functional capability at some late age, than will chronological age' [@R3].

Data from industrialized countries on the impact of HIV on accelerated ageing may be confounded by differential risk exposure by HIV status to risk factors, such as smoking and alcohol consumption. Moreover, lower socioeconomic status and poor diet are also associated with accelerated biological ageing [@R4]. Thus, the NIH Office of AIDS Research has highlighted the need for carefully designed studies of HIV and ageing that takes these factors into account [@R5]. Assessment of biological ageing in HIV infection in sub-Saharan Africa may also be influenced by coexisting morbidities, malnutrition, a high prevalence of enteric pathogens and opportunistic coinfections and epigenetic variation [@R6; @R7]. Thus, data related to biological ageing and HIV obtained from well resourced settings may not be directly translatable to African populations. However, few data are available from sub-Saharan Africa populations [@R8] where three million people aged 50 years and older are living with HIV [@R9]. If premature biological ageing is associated with HIV, then age-related morbidity in HIV-infected individuals is likely to place a significant burden on healthcare systems in sub-Saharan Africa.

Telomeric DNA length is a widely used BoA. Telomeres are nucleoprotein complexes at the ends of eukaryotic chromosomes. Their DNA component shortens with somatic cell division, and upon reaching a critically short length, a DNA damage signal leads to cell cycle arrest, resulting in replicative senescence [@R10; @R11]. Telomere shortening is associated with increasing chronological age, and a wide range of diseases, including cardiovascular disease [@R12] and renal dysfunction [@R13]. Telomere attrition is affected by psychosocial confounders, genetics and potentially by nucleoside reverse transcriptase inhibitors (NRTIs) [@R14]. Expression levels of the cell cycle regulator CDKN2A may represent a more robust BoA [@R15]. CDKN2A acts as a tumour suppressor and maintains cells in a state of growth arrest both in replicative and stress-induced premature senescence. Increasing levels of CDKN2A transcriptional expression occur with increasing age both in solid organs and peripheral blood leukocytes (PBLs) [@R16]. In the former, increasing CDKN2A expression correlates directly with decreasing function.

This cross-sectional study conducted in South Africa was undertaken to provide a rapid assessment of whether there was evidence that HIV-infected individuals had advanced biological ageing compared with HIV-seronegative individuals by comparing telomere length and CDKN2A expression.

Materials and methods
=====================

Ethics statement
----------------

The study was approved by the Ethics Committees of the London School of Hygiene and Tropical Medicine and the University of Cape Town Faculty of Health Sciences, and was adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants.

Study participants
------------------

HIV-infected individuals aged at least 30 years were enrolled from a community-based HIV treatment centre in Nyanga district in Cape Town [@R17]. All participants had a confirmed serological diagnosis of HIV and either about to commence antiretroviral therapy (ART; ART-naive) or were already on first-line ART. HIV-seronegative participants were recruited using frequency-matching by sex and 5-year age categories. HIV-seronegative individuals were enrolled from participants confirmed to be HIV-seronegative attending an HIV prevention trials centre (Emavundleni Centre). These two centres were chosen, as attendees were drawn from the same community and therefore likely to have similar sociodemographic characteristics.

Data and sample collection
--------------------------

Sociodemographic information and medical history were obtained by questioning participants in their first language (Xhosa or English). Data collected included factors known to affect ageing \[e.g. indoor/outdoor occupation as a proxy for ultraviolet (UV) exposure\]. Clinical information was available relating to current and nadir CD4^+^ cell counts, peak and current HIV plasma viral load and WHO clinical status. Venous blood was collected at the time of participant interview to measure telomere length and CDKN2A expression in PBL.

DNA/RNA extraction
------------------

DNA was extracted from PBLs using the Maxwell Automated Purification System according to manufacturer\'s instructions (Promega, Madison, Wisconsin, USA). DNA concentration and purity was quantified by Nanodrop Spectrophotometer (ThermoFisher Scientific, Waltham, Massachusetts, USA). RNA was extracted using Trizol reagent (Invitrogen, Life Technologies, Grand Island, New York, USA) following manufacturer\'s guidelines. DNA/RNA extraction was performed in Cape Town and samples shipped on dry ice to the University of Glasgow.

Telomere length determination
-----------------------------

Telomere lengths were determined by quantitative PCR (qPCR) following the method of Cawthon [@R18]. Telomere length determination was performed blindly using a Roche Light Cycler (Roche Diagnostics, Indianapolis, Indiana, USA) LC480. Briefly, telomere length analyses were performed in triplicate for each sample, using a single-copy gene amplicon primer set (acidic ribosomal phosphoprotein, 36B4) and a telomere-specific amplicon primer set [@R19]. Quality control parameters for the amplifications comprised a cut-off of 0.15 for the standard deviation (SD) of the threshold cycle (Ct) for sample replicates. At a SD above 0.15, the sample was reanalysed. The average SD across plates was 0.05. Relative telomere length was estimated from Ct scores using the comparative Ct method after confirming that telomere and control gene assays yielded similar amplification efficiencies. This method determines the ratio of telomere repeat copy number to single copy gene number (T/S) ratio in experimental samples relative to a control sample DNA. This normalized T/S ratio was used as the estimate of relative telomere length (Relative T/S). The interassay variation was assessed by comparing the relative telomere estimates (T/S ratio) estimates across assays for the positive controls, assayed on every assay plate. The average interassay coefficient of variance was 0.6% for telomere length and 0.23% for 36B4, with coefficient of variances comparable to previous data from this laboratory [@R20; @R21].

CDKN2A expression determination
-------------------------------

Relative quantitative real-time PCR (qRT-PCR) was used to estimate mRNA levels corresponding to the candidate senescence associated gene *CDKN2A* in line with established methodology [@R19; @R22]. Expression levels were measured against a reference hypoxanthine phosphoribosyltransferase (HPRT) housekeeping gene on an ABI Prism(R) 7500 Sequence Detection System. Sequences of human TaqMan Primer/Probe sets were designed by Primer Express algorithm (Applied Biosystems, Austin, Texas, USA). The comparative threshold cycle method (ΔΔCT) [@R23] was employed to quantify relative gene expression.

Statistical analysis
--------------------

Analyses were performed using Stata 12 (Stata Corp, College Station, Texas, USA). Clinical and biochemical data were summarized as the median with interquartile range (IQR) or mean with standard error (SE), as appropriate. Analyses were conducted on log~10~-transformed values of telomere length and mean CDKN2A expression to satisfy the assumption of normally distributed residuals. Results are displayed back-transformed to the original scale. Univariable analyses were performed to assess the relationships between mean telomere length, CDKN2A expression, HIV status and other clinical/demographic categories. Multivariable linear regression was used to examine the relationships of biomarker expression with HIV status adjusting for confounders identified in the univariable analysis and for *a priori* defined confounders (age and sex).

Results
=======

Participant characteristics
---------------------------

Characteristics of the 236 HIV-infected individuals and 250 age/sex frequency matched HIV-seronegative individuals are reported in [Table 1](#T1){ref-type="table"}. All participants were of African ancestry. Telomere data were available for all participants, and CDKN2A data for 444 participants (91.4%). The majority (75%) of the study population was female. The median age of the HIV-infected population was 39 years (IQR 35--46 years), similar to the HIV-seronegative group (median 40 years (IQR 35--49 years)) (*P* = 0.17). HIV-infected participants tended to be of higher socioeconomic status and were less likely to smoke or consume alcohol ([Table 1](#T1){ref-type="table"}). Cases also had a lower mean BMI and were more likely to have current or previous tuberculosis (TB) than HIV-seronegative individuals. Overall, 87.1% of HIV-infected participants were receiving ART and the current CD4^+^ cell count among these participants was 468 cells/μl (IQR 325--607 cells/μl) and 84.3% had an undetectable viral load (\<50 copies/ml). All participants on ART received a regimen that contained an NRTI.

Biological age and chronological age in HIV-seronegative individuals
--------------------------------------------------------------------

Telomere length and CDKN2A levels were validated against chronological age in HIV-seronegative individuals. As expected, there was a negative association between chronological age and telomere length (Pearson *r* = −0.13, *P* = 0.05), and a positive association with CDKN2A expression (*r* = 0.16, *P* = 0.02). The relationship between CDKN2A expression and age was similar in men and women. However, for telomere length, age-related attrition was somewhat greater in men than in women, but this difference did not reach statistical significance (*r* = −0.25 vs. *r* = −0.09, *P*-interaction = 0.13).

Biological age and HIV status
-----------------------------

Telomere length was significantly shorter in HIV-infected individuals than in HIV-seronegative individuals \[mean relative T/S ratio (Rel T/S) ± SE: 0.91 ± 0.007 vs. 1.07 ± 0.008, *P* \< 0.0001, [Fig. 1](#F1){ref-type="fig"}a\]. Telomere length decreased with chronological age in HIV-infected individuals (*r* = −0.15, *P* = 0.03). Mean CDKN2A expression was higher in HIV-infected participants than in HIV-seronegative individuals (0.45 ± 0.02 vs. 0.36 ± 0.03, *P* = 0.003, [Fig. 1](#F1){ref-type="fig"}b, [Table 2](#T2){ref-type="table"}), and there was little evidence of correlation between chronological age and CDKN2A expression in HIV-infected individuals (*r* = 0.09, *P* = 0.17). No interactions were detected with HIV status when assessing the relationship between biomarkers and chronological age (data not shown).

![Assessment of biomarkers (telomere length and CDKN2A) in peripheral blood leukocytes.](aids-27-2375-g001){#F1}

Among the HIV-infected patients, there was no evidence that either telomere length or CDKN2A expression was associated with ART status (*P* = 0.71 telomere length; *P* = 0.80 CDKN2A; [Table 2](#T2){ref-type="table"}).

Among the 172 participants on ART with viral suppression, current CD4^+^ cell count was positively associated with telomere length and negatively associated with CDKN2A expression (*P*-trend = 0.02 telomere length; *P*-trend = 0.05 CDKN2A; [Table 3](#T3){ref-type="table"}). There was no evidence of an association between these BoA and CD4^+^ cell count in patients with detectable viral load (data not shown).

Biological age and sociodemographic characteristics
---------------------------------------------------

As sociodemographic characteristics may be associated with biological ageing [@R4; @R24], we analysed their association with the two BoA, stratified by HIV status ([Table 4](#T4){ref-type="table"}a,b). HIV-infected participants aged at least 50 years had significantly shorter telomeres than HIV-seronegative individuals in the same age group (mean RelT/S 0.84 vs. 1.01, *P* = 0.03; [Table 4](#T4){ref-type="table"}a). There were no significant associations between telomere length and other sociodemographic variables for HIV-infected participants. In HIV-seronegative individuals, an association with alcohol consumption and telomere length was detected, with those who did not consume alcohol and those who consumed more than 1 l/week having the shortest telomere lengths (*P* = 0.04) ([Table 4](#T4){ref-type="table"}a). For CDKN2A expression, the only evidence of an association was among HIV-seronegative individuals, in whom CDKN2A expression was higher among those with lower incomes than among those with higher incomes (mean RelT/S 0.39 vs. 0.30, *P* = 0.03; [Table 4](#T4){ref-type="table"}b).

Discussion
==========

Levels of two validated biomarkers of ageing (telomere length and CDKN2A expression) were found to be consistent with increased biological ageing in South African HIV-infected individuals compared with age and sex-matched HIV-seronegative controls. This important finding is supported by our previous observations in this same study population that HIV infection is associated with increased frequency of a frailty phenotype [@R25], and changes in retinal vessel calibre, lens density and corneal endothelial cells that are consistent with increased biological ageing [@R26; @R27; @R28]. Among patients receiving ART and in whom plasma viral load was suppressed, the biological ageing estimated by both biomarkers was greatest in those with low current CD4^+^ cell counts. Although long-term prospective cohort studies will be required to definitively characterize the impact of HIV on biological ageing in sub-Saharan Africa, the combination of these case--control biomarker data and the existing frailty and ocular phenotypic data provide a strong evidence base on which to justify future long-term studies.

Both biomarkers were strongly associated with chronological age in HIV-seronegative individuals, validating their use as BoAs. Reduced telomere length is associated with markers of low socioeconomic status in industrialized countries [@R4; @R24]. Lower income was associated with increased CDKN2A expression in HIV-seronegative individuals, but socioeconomic factors were not associated with either BoA in HIV-infected participants. Adjustment for socioeconomic factors did not alter estimates of BoA between HIV-infected participants and HIV-seronegative individuals, suggesting that HIV infection, rather than social deprivation, is the main driver of biological ageing in this population.

Ageing reflects an accumulation of multiple molecular deficits in varying organ systems [@R29]. Interindividual differences in rates of ageing have prompted the search for informative biomarkers of biological ageing. Measurement of telomere length in PBLs is the standard method of evaluating biological ageing in epidemiological studies, with changes in PBL telomere length in effective synchrony with changes in telomere length in solid organs, thus providing a suitable surrogate for biological age in the whole organism [@R30; @R31]. However, there is potential for confounding by methodological and design difference between studies [@R15]. The number of techniques available for telomere length measurement highlights that no one technique is entirely satisfactory [@R32]. Southern blotting of terminal restriction fragments, single telomere length analysis (STELA) and real-time qPCR (qPCR) may also be used to assess telomere length in PBLs. We chose to use qPCR, as it is the most suitable methodology for high-throughput analyses [@R15; @R33]. Although interassay comparisons are very good (as evidenced by our coefficient of variance of 0.6%), intra-laboratory comparisons can be poor [@R34]. Logistical and budgetary constraints precluded assessment of telomere length in T-cell subsets, a methodology to address telomere dynamics advocated previously for investigation in the context of HIV infection [@R35]. Although we acknowledge that this methodology would give a higher resolution data set, the primary aim of this study was to provide preliminary data to inform future work, and assessment of telomere length in PBLs has been the approach used by others in this field [@R36; @R37].

In view of these methodological issues, we elected to measure an additional BoA, CDKN2A. CDKN2A expression increases with increasing chronological age in PBLs and solid organs [@R16; @R19; @R22], and it functions as a direct marker of cellular growth arrest [@R16]. CDKN2A represents a superior BoA to telomere length when judged by the Baker and Sprott criterion [@R3]. It can be a stronger predictor of function than chronological age and displays less interindividual variation [@R19; @R22]. CDKN2A expression was substantially greater in HIV-infected adults than in age-matched HIV-seronegative individuals. As well as functioning as a tumour suppressor, CDKN2A is also a component of stress-induced premature senescence [@R38], which prevents T-cell replication following acute insult [@R39]. The decoupling of the relationship between CDKN2A expression and chronological age in HIV-infected individuals is a direct consequence of HIV-associated premature T-cell senescence [@R2], and lack of further T-cell replication with HIV infection. Nelson *et al.*[@R40] found that ART-naive individuals had higher levels of CDKN2A expression than HIV-seronegative individuals, and suggested that active HIV replication accounted for elevated expression. Our data show that with viral suppression and ART, high levels of CDKN2A are still detectable. Thus, high rates of HIV replication are not a prerequisite for continued, elevated expression of this biomarker.

Both biomarkers were significantly associated with current CD4^+^ cell count in those receiving ART in whom viral load was undetectable. Increased CDKN2A expression was associated with lower CD4^+^ cell counts, consistent with the finding that CDKN2A expression is inversely related to T-cell replicative capacity [@R39]. Telomere length was also shorter in participants on ART with lower current CD4^+^ cell counts. Thus, levels of both BoA suggested that lower current CD4^+^ cell counts were associated with greater biological ageing. Human telomerase comprises a reverse transcriptase sharing homology with the HIV reverse transcriptase [@R41]. It is plausible that ART may inhibit its activity, leading to differences in telomere lengths between ART-naive and treated groups. Previous studies have produced inconsistent findings regarding such an association [@R36; @R42; @R43]. Comparison of levels in treated and ART-naive groups in our study did not support this potential mechanism, and furthermore, neither BoA was associated with ART duration. It should, however, be noted that dynamic changes over time in the PBL composition of the blood during ART may account for some of the observed effects, reflecting a potential limitation of using mixed PBLs in this context.

Although we have demonstrated a substantial effect of HIV infection on biological ageing, estimating the magnitude of the effect is challenging. One important reason is because disease states can cause stress-induced premature senescence [@R38], leading to acute growth arrest (in contrast to gradual replicative senescence). Thus, the 'rate of biological ageing' may not be accurately predicted in HIV infection. In other words, HIV-infected individuals effectively display a biological age observed in older uninfected individuals due to disease-induced stress. Therefore, quantification in terms of an effective biological age difference between infected and uninfected individuals is problematic, as the component of stress-induced premature senescence in infected individuals will be missing in uninfected controls, whereas in turn, replicative senescence may be accelerated due to disease stress. Estimation of telomere length as a function of given chronological age has been quantified [@R35; @R44]; however telomere length as an isolated measure at a given age may be imprecise, reflecting psychosocial, genetic and epigenetic confounders. The predictive capability of CDKN2A in determining effective biological age is relatively novel [@R16], and as CDKN2A expression is related to cellular growth arrest, it may not be subject to similar attrition phenomena [@R19; @R22; @R33]. Future work should involve development of methods to establish quantification of differences in effective biological age in disease states wherein stasis is involved. Any measure of the difference in biological age between HIV-infected and HIV-seronegative individuals will also have to be viewed in a functional context between these two groups, wherein differences in biochemical parameters, such as interleukin-6, CD14 and D-dimer, are also addressed [@R45]. Inflammation and activation of coagulation pathways are central to the pathophysiology leading to morbidity. Immune activation is a hallmark of chronic HIV infection and may be mediated by several mechanisms: increased pathogen burden as a result of impaired immunity, chronic viral replication of HIV and other viruses (e.g. cytomegalovirus, hepatitis viruses) and microbial translocation of bacterial products across damaged mucosa (e.g. in the gut). These factors may also need to be correlated to biomarkers of ageing to fully elucidate accelerated ageing trajectories in HIV infection.

A key strength of our study is the inclusion of an age and sex-matched control group with a similar sociodemographic profile as the HIV-infected participants. The hypothesis of accelerated ageing in HIV has received criticism due to limitations in characterization of participants, particularly the possibility of differential exposure to potential risk factors between HIV-infected and uninfected populations [@R46]. As the HIV epidemic in South Africa is generalized and recruitment took place from the same community, the likelihood of differential exposure was minimized. The study design means that 'survivor effects' cannot be excluded. Individuals with poor biological ageing may die earlier; thus, participants comprise survivors with different biological characteristics to nonsurvivors. However, recruitment of individuals from similar socioeconomic backgrounds should have limited potential confounding and survivor effects. The differences in smoking and alcohol consumption between the two groups could be due to HIV-infected participants modifying their smoking and alcohol consumption behaviours in response to lifestyle counselling. However, it is also plausible that the reported differences are due to misclassification, with HIV-infected participants wanting to demonstrate 'healthy behaviour', possibly leading to confounding. We used location of work as a proxy measure of UV exposure, which may also have been confounded by socioeconomic status. The sex composition of participants was three-quarters female, consistent with the characteristics of the clinic cohort from where our participants were enumerated [@R47], and reflective of the African AIDS epidemic. Lastly, as all our study participants are of African ancestry, our results are only generalizable to the African population.

The AIDS epidemic in sub-Saharan Africa is entering a new phase wherein HIV-infected individuals are living longer and may be ageing faster [@R9; @R48]. Our data indicate increased biological ageing in HIV-infected individuals compared with HIV-seronegative individuals. The increased number of older HIV-infected individuals in this region, compounded by accelerated biological ageing, may have wide-ranging implications for HIV management. Delivery of healthcare systems integrating HIV treatment and age-related morbidity may be necessary to manage this phase of the epidemic.

In light of these findings, important research questions arise: prospective assessment of biological age in HIV-infected and HIV-seronegative individuals is needed to ascertain whether the accelerated ageing trajectory develops as soon as HIV infection is acquired. Further questions include whether biological age is dependent upon the duration of untreated disease or nadir CD4^+^ cell count, and if the biological age of the two groups continues to diverge during long-term ART, or rather is modified by ART. Finally, assessment of the relative contributions of HIV and ART towards biological ageing may provide mechanistic insight.

In summary, greater biological age, as determined by shorter telomere length and higher CDKN2A expression, is associated with HIV infection in South Africa. The 'ageing of the HIV epidemic' poses many challenges and these may be amplified by accelerated biological ageing, potentially resulting in important health and social implications for the millions of patients receiving ART in Africa.

Acknowledgements
================

The authors wish to thank the staff and patients at the recruitment sites, the Department of Ophthalmology, Groote Schuur Hospital, Cape Town and DHL (Z.A.) for assistance with sample logistics and transport from Cape Town to Glasgow.

S.P. conceived and designed experiments; undertook clinical data collection; statistical analysis; wrote first draft; did the critical revision and provided intellectual input to further drafts. S.D.L. designed the experiments; did the critical revision and provided intellectual input to further drafts. C.G. conceived and designed the experiments; did the critical revision and provided intellectual input to further drafts. D.M. and L.M. did the laboratory data analysis; critical revision and provided intellectual input to further drafts. H.W. did the statistical analysis; critical revision and provided intellectual input to further drafts. J.P. T.C.. and KP carried out the laboratory data analysis. L.G.B. and R.W. did the critical revision and provided intellectual input to further drafts. P.G.S. conceived and designed the experiments; did the critical revision and provided intellectual input to further drafts.

This work was funded by a Wellcome Trust grant awarded to S.P. (Grant number: 090354/Z/09/Z). S.D.L. is funded by the Wellcome Trust, London (Grant number: 088590). R.W. is supported by IEDEAA, International Epidemiologic Database to Evaluate AIDS (Grant number: 5U01AI069924-02) and CEPAC Cost-Effectiveness of Preventing AIDS Complications 5 (R01AI058736-02).

The funders played no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Conflicts of interest
---------------------

The authors have no conflicts of interest to declare.

Correspondence to Dr Sophia Pathai, International Centre for Eye Health, Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Tel: +44 20 7958 8343; fax: +44 20 7958 8325; e-mail: <Sophia.pathai@lshtm.ac.uk>

###### 

Characteristics of study population.

  Variable                                                                            HIV-infected participants (236) % (*n*)         HIV-seronegative participants (250) % (*n*)     *P*
  ----------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------
  Age (years)                                                                         39 (35--46)[^a^](#TF1-1){ref-type="table-fn"}   40 (35--49)[^a^](#TF1-1){ref-type="table-fn"}   0.17
  Age (years) by group                                                                                                                                                                
   30--39                                                                             50.4 (119)                                      46.4 (116)                                      
   40--49                                                                             32.6 (77)                                       32.0 (80)                                       0.41
   \>50                                                                               17.0 (40)                                       21.6 (54)                                       
  Male sex                                                                            25.4 (60)                                       24.0 (60)                                       0.72
  Education                                                                                                                                                                           
   \<High school                                                                      11.9 (28)                                       17.6 (44)                                       0.08
   High school or tertiary education                                                  88.1 (208)                                      82.4 (206)                                      
  Income                                                                                                                                                                              
   \<US\$ 125/month                                                                   56.8 (134)                                      67.2 (168)                                      0.02
   \>US\$ 125/month                                                                   43.2 (102)                                      32.8 (82)                                       
  Housing                                                                                                                                                                             
   Informal                                                                           47.9 (113)                                      40.4 (101)                                      0.10
   Formal                                                                             52.1 (123)                                      59.6 (149)                                      
  Water supply                                                                                                                                                                        
   Shared                                                                             75.0 (177)                                      74.0 (185)                                      0.80
   Own                                                                                25.0 (59)                                       26.0 (65)                                       
  Alcohol (amount per week)                                                                                                                                                           
   Nil                                                                                69.5 (164)                                      56.4 (141)                                      
   Up to 1 l/week                                                                     20.3 (48)                                       21.6 (54)                                       0.001
   \>1 l/week                                                                         10.2 (24)                                       22.0 (55)                                       
  Duration of smoking (years)                                                                                                                                                         
   Nil                                                                                84.8 (200)                                      72.0 (180)                                      
   \<10 years                                                                         5.1 (12)                                        12.8 (32)                                       0.002
   \>10 years                                                                         10.2 (24)                                       15.2 (38)                                       
  Illicit drugs                                                                                                                                                                       
   Never taken                                                                        97.4 (222)                                      98.0 (240)                                      
   Ever taken                                                                         2.6 (6)                                         2.0 (5)                                         0.67
  BMI (kg/m^2^)                                                                       27.8 ± 0.4                                      31.5 ± 0.6                                      \<0.0001
  Comorbidity (including hypertension)                                                                                                                                                
   None                                                                               64.4 (152)                                      55.2 (138)                                      
   One or more                                                                        35.6 (84)                                       44.8 (112)                                      0.04
  TB status                                                                                                                                                                           
   No history                                                                         32.6 (77)                                       87.6 (219)                                      
   Current                                                                            4.2 (10)                                        0.4 (1)                                         \<0.0001
   Previous                                                                           63.1 (149)                                      12.0 (30)                                       
  HIV characteristics % (*n*) or median (IQR)                                                                                                                                         
  WHO stage                                                                                                                                                                           
   1/2                                                                                27.1 (67)                                                                                       
   3/4                                                                                72.3 (181)                                                                                      
  ART naive                                                                           12.9 (32)                                                                                       
  CD4^+^ cell count in ART-naive group (*n* = 32)                                     182 (84--202)                                                                                   
  Log~10~VL in ART-naive group (*n* = 21)                                             4.88 (4.21--5.18)                                                                               
  Current CD4^+^ cell count in ART group (cells/μl)                                   468 (325--607)                                                                                  
  Nadir CD4^+^ cell count in ART group                                                128 (76--171)                                                                                   
  \% with undetectable VL[^b^](#TF1-2){ref-type="table-fn"} in ART group (cells/μl)   84.3 (172)                                                                                      
  Peak log~10~VL in ART group                                                         4.56 (3.84--4.98)                                                                               
  Duration of ART, months                                                             58 (34--75)                                                                                     

ART, antiretroviral therapy; TB, tuberculosis; VL, viral load.

^a^Values expressed as median (interquartile range).

^b^Undetectable VL refers to VL \<50 copies/ml.

###### 

Association of HIV states with telomere length and CDKN2A expression.

  Clinical group            *N*   Telomere length Mean Rel T/S (95% CI)   *P*                                          *N*   Mean CDKN2A expressio*n* (95% CI)   *P*
  ------------------------- ----- --------------------------------------- -------------------------------------------- ----- ----------------------------------- -----------------------------------------
  HIV-seronegative                                                                                                                                               
                            250   1.07 (1.04--1.11)                       \<0.0001[^a^](#TF2-1){ref-type="table-fn"}   217   0.35 (0.32--0.39)                   0.006[^a^](#TF2-1){ref-type="table-fn"}
  HIV-infected;                                                                                                                                                  
  On ART                    204   0.91 (0.87--0.94)                                                                    199   0.45 (0.40--0.50)                   
  HIV-infected; ART-naive                                                                                                                                        
                            32    0.89 (0.81--0.98)                       0.71[^b^](#TF2-2){ref-type="table-fn"}       28    0.46 (0.34--0.62)                   0.80[^b^](#TF2-2){ref-type="table-fn"}

ART, antiretroviral therapy; CI, confidence interval.

^a^*P* value for HIV-seronegative individuals vs. HIV-infected participants overall.

^b^*P* value between HIV group (i.e. on ART and ART-naive).

###### 

Association of biomarkers with HIV-related covariates.

  Variable                               *N* = 172   Telomere length Mean Rel T/S (95% CI)   *P*        *N* = 168   Mean CDKN2A (95% CI)   *P*
  -------------------------------------- ----------- --------------------------------------- ---------- ----------- ---------------------- ----------
  WHO stage                                                                                                                                
   1/2                                   33          0.89 (0.81--0.97)                                  32          0.44 (0.35--0.56)      
   3/4                                   139         0.92 (0.88--0.96)                       0.48       136         0.46 (0.41--0.51)      0.81
  Duration of ART (months)                                                                                                                 
   0--36                                 40          0.86 (0.80--0.93)                       0.10^\*^   39          0.51 (0.41--0.63)      0.17^\*^
   36--72                                80          0.91 (0.87--0.97)                                  79          0.45 (0.39--0.52)      
   \>72                                  52          0.95 (0.88--1.01)                                  50          0.42 (0.35--0.51)      
  Current CD4^+^ cell count (cells/μl)                                                                                                     
   \<200                                 7           0.85 (0.70--1.02)                       0.02^\*^   7           0.63 (0.38--1.03)      0.05^\*^
   201--350                              37          0.83 (0.77--0.91)                                  37          0.52 (0.42--0.64)      
   \>351                                 128         0.93 (0.90--0.98)                                  124         0.43 (0.38--0.48)      
  Nadir CD4^+^ cell count (cells/μl)                                                                                                       
   \<200                                 153         0.91 (0.87--0.94)                       0.58       151         0.46 (0.41--0.51)      0.80
   \>201                                 19          0.93 (0.83--1.05)                                  17          0.44 (0.32--0.61)      
  Peak viral load                                                                                                                          
   \<10 000 copies                       52          0.92 (0.86--0.99)                                  51          0.50 (0.42--0.61)      
   \>10 000 copies                       120         0.91 (0.87--0.95)                       0.68       117         0.44 (0.38--0.48)      0.27
  TB status                                                                                                                                
   No history                            48          0.91 (0.84--0.97)                                  47          0.47 (0.39--0.57)      
   Current /previous history             124         0.91 (0.87--0.95)                       0.92       121         0.45 (0.40--0.51)      0.69

Linear regression adjusted for age in participants on ART with suppressed VL (i.e. \<50 copies/ml). ART, antiretroviral therapy; CI, confidence interval; TB, tuberculosis; VL, viral load. ^\*^*P* value test for trend.

###### 

\(a\) Mean telomere length (RelT/S) in HIV-infected participants and HIV-seronegative individuals, adjusted for age.

  Variable                    *N*   HIV-infected participants Telomere length Mean Rel T/S (95% CI)   *P*        *N*   HIV-seronegative participants Telomere length Mean Rel T/S (95% CI)   *P*
  --------------------------- ----- ----------------------------------------------------------------- ---------- ----- --------------------------------------------------------------------- ----------
  Age (years)                                                                                                                                                                                
   30--39                     119   0.92 (0.88--0.96)                                                            116   1.10 (1.04--1.15)                                                     
   40--49                     77    0.93 (0.88--0.98)                                                 0.11       80    1.09 (1.02--1.15)                                                     0.09^\*^
   \>50                       40    0.84 (0.77--0.91)                                                            54    1.01 (0.94--1.08)                                                     
  Sex                                                                                                                                                                                        
   Male                       60    0.92 (0.86--0.99)                                                            60    1.04 (0.97--1.12)                                                     
   Female                     176   0.90 (0.87--0.94)                                                 0.56       190   1.08 (1.04--1.12)                                                     0.30
  Income/month (US\$)                                                                                                                                                                        
   \<US\$ 125/month           134   0.91 (0.87--0.95)                                                            168   1.07 (1.02--1.12)                                                     
   \>US\$ 125/month           102   0.90 (0.85--0.95)                                                 0.86       82    1.07 (1.00--1.14)                                                     0.94
  UV exposure/occupation                                                                                                                                                                     
   Outdoor worker             155   0.90 (0.86--0.94)                                                 0.69       178   1.08 (1.04--1.13)                                                     0.30
   Indoor worker              81    0.92 (0.87--0.97)                                                            72    1.04 (0.98--1.12)                                                     
  Education                                                                                                                                                                                  
   \<High school              28    0.91 (0.82--1.01)                                                            44    1.04 (0.96--1.11)                                                     
   High school/college        208   0.91 (0.87--0.94)                                                 0.91       206   1.08 (1.04--1.12)                                                     0.49
  Housing                                                                                                                                                                                    
   Formal                     123   0.91 (0.87--0.96)                                                            149   1.06 1.02--1.11                                                       
   Informal                   113   0.90 (0.86--0.95)                                                 0.69       101   1.09 1.03--1.15                                                       0.77
  Duration of smoking                                                                                                                                                                        
   Nil                        200   0.91 (0.88--0.95)                                                            180   1.08 (1.03--1.12)                                                     
   \<10 years                 12    0.93 (0.80--1.08)                                                 0.36       32    1.07 (0.97--1.17)                                                     0.92
   ≥10 years                  24    0.85 (0.77--0.95)                                                            38    1.07 (0.98--1.16)                                                     
  Alcohol (amount per week)                                                                                                                                                                  
   Nil                        164   0 . 92 (0.86--0.96)                                               0.18^\*^   141   1.08 (1.03--1.13)                                                     0.04
   \<1 l                      48    0.89 (0.82--0.95)                                                            54    1.13 (1.05--1.22)                                                     
   \>1 l                      24    0.86 (0.77--0.95)                                                            55    1.00 (0.93--1.08)                                                     
  BMI (kg/m^2^)                                                                                                                                                                              
   \<25                       87    0.88 (0.83--0.93)                                                 0.08       60    1.04 (0.97--1.11)                                                     0.35
   25--29.9                   71    0.96 (0.90--0.98)                                                            55    1.12 (1.04--1.20)                                                     
   \>30                       78    0.90 (0.85--0.95)                                                            135   1.07 (0.98--1.12)                                                     
  Comorbid condition                                                                                                                                                                         
   No                         152   0.91 (0.87--0.95)                                                            138   1.08 (1.04--1.14)                                                     
   Yes                        84    0.90 (0.85--0.95)                                                 0.88       112   1.06 (1.00--1.11)                                                     0.65
  TB status                                                                                                                                                                                  
   No history                 77    0.90 (0.85--0.96)                                                 0.88       219   1.07 (1.03--1.11)                                                     0.71
   Current/past               159   0.91 (0.87--0.95)                                                            31    1.09 (0.99--1.20)                                                     

  --------------------------------------------------------------------------------------------------------------------- ----- --------------------------------------- ---------- ----- ------------------------------------------- -------
  **(b) Relative CDKN2A expression in HIV-infected participants and HIV-seronegative individuals, adjusted for age.**                                                                                                              
  Variable                                                                                                              *N*   HIV-infected participants Mean CDKN2A   *P*        *N*   HIV-seronegative participants Mean CDKN2A   *P*
  Age (years)                                                                                                                                                                                                                      
   30--39                                                                                                               113   0.41 (0.36--0.47)                                  98    0.29 (0.25--0.35)                           
   40--49                                                                                                               74    0.45 (0.38--0.53)                       0.04^\*^   70    0.44 (0.37--0.54)                           0.006
   \>50                                                                                                                 40    0.54 (0.43--0.68)                                  49    0.38 (0.30--0.48)                           
  Sex                                                                                                                                                                                                                              
   Male                                                                                                                 59    0.42 (0.35--0.50)                                  53    0.37 (0.30--0.47)                           
   Female                                                                                                               168   0.45 (0.41--0.51)                       0.46       163   0.35 (0.31--0.40)                           0.71
  Income/month (US\$)                                                                                                                                                                                                              
   \<US\$ 125/month                                                                                                     129   0.43 (0.38--0.48)                                  145   0.39 (0.34--0.44)                           
   \>US\$ 125/month                                                                                                     98    0.47 (0.41--0.54)                       0.44       72    0.30 (0.23--0.37)                           0.03
  UV exposure/occupation                                                                                                                                                                                                           
   Outdoor worker                                                                                                       147   0.45 (0.40--0.50)                                  155   0.36 (0.32--0.41)                           
   Indoor worker                                                                                                        80    0.45 (0.38--0.52)                       0.81       62    0.34 (0.28--0.42)                           0.86
  Education                                                                                                                                                                                                                        
   \<High school                                                                                                        27    0.48 (0.36--0.64)                                  39    0.34 (0.26--0.44)                           
   High school/college                                                                                                  200   0.44 (0.40--0.49)                       0.60       178   0.36 (0.32--0.41)                           0.66
  Housing                                                                                                                                                                                                                          
   Formal                                                                                                               121   0.44 (0.39--0.50)                                  126   0.34 (0.30--0.40)                           
   Informal                                                                                                             106   0.45 (0.40--0.52)                       0.63       91    0.37 (0.31--0.44)                           0.47
  Duration of smoking                                                                                                                                                                                                              
   Nil                                                                                                                  192   0.45 (0.40--0.49)                                  157   0.36 (0.31--0.40)                           
   \<10 years                                                                                                           12    0.65 (0.43--0.93)                       0.08       27    0.43 (0.31--0.58)                           0.23
   \>10 years                                                                                                           23    0.36 (0.28--0.49)                                  33    0.30 (0.22--0.43)                           
  Alcohol (amount per week)                                                                                                                                                                                                        
   Nil                                                                                                                  155   0 . 45 (0.40--0.50)                                126   0.35 (0.30--0.40)                           
   \<1 l                                                                                                                48    0.44 (0.36--0.54)                       0.72       42    0.36 (0.28--0.47)                           0.87
   \>1 l                                                                                                                24    0.41 (0.31--0.55)                                  49    0.37 (0.29--0.47)                           
  BMI (kg/m^2^)                                                                                                                                                                                                                    
   \<25                                                                                                                 82    0.41 (0.36--0.49)                                  55    0.33 (0.26--0.41)                           
   25--29.9                                                                                                             69    0.49 (0.41--0.57)                       0.44       46    0.38 (0.30--0.48)                           0.59
   \>30                                                                                                                 76    0.45 (0.38--0.52)                                  116   0.36 (0.31--0.42)                           
  Comorbid condition                                                                                                                                                                                                               
   No                                                                                                                   144   0.44 (0.38--0.48)                                  119   0.39 (0.34--0.46)                           
   Yes                                                                                                                  83    0.46 (0.41--0.55)                       0.73       98    0.32 (0.26--0.38)                           0.08
  TB status                                                                                                                                                                                                                        
   No history                                                                                                           73    0.45 (0.38--0.53)                       0.93       191   0.36 (0.32--0.40)                           0.80
   Current/past                                                                                                         154   0.44 (0.40--0.50)                                  26    0.34 (0.25--0.48)                           
  --------------------------------------------------------------------------------------------------------------------- ----- --------------------------------------- ---------- ----- ------------------------------------------- -------

CI, confidence interval; TB, tuberculosis. ^\*^*P* value test for trend.
